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Neuropathology is important to understand the normal aging-related changes versus disease-
related pathologic changes. The recent description of a harmonized evaluation strategy to 
evaluate aging-related tau astrogliopathy (ARTAG) aimed to facilitate our understanding of 
its relevance. In the present study we evaluated how consistently neuropathologists recognize 
i) different astroglial tau immunoreactivities including those of ARTAG and those associated 
with primary tauopathies (study 1); ii) ARTAG types (study 2A); and iii) the severity of 
ARTAG (study 2B). A total of twenty-two cases were selected for these studies. For study 1, 
thirty-five microphotographs of astrocytic tau AT8 stained immunoreactivities were provided. 
For study 2A+B, AT8 immunostained sections representing different anatomical regions were 
scanned and made available for download and review. Percentage (%) of agreement and 
kappa values with 95% confidence interval (CI) were calculated for each evaluation. The 
overall agreement for study 1 was > 60% with a kappa value of 0.54 (95% CI 0.433, 0.645). 
Good agreement (> 90%, kappa: 0.48, 95% CI 0.457, 0.900) was reached in study 2A for the 
identification of ARTAG pathology and also for each ARTAG type (kappa: 0.37-0.71). Less 
agreement (kappa: 0.39, 95% CI 0.341, 0.445) was reached for the evaluation of ARTAG 
severity. The overall assessment of ARTAG showed good agreement (kappa: 0.59, 95% CI 
0.534,0.653) between raters. Our study supports the application of the current harmonized 
evaluation strategy of ARTAG with a slight modification of the evaluation of its severity. 
This allows comparison of worldwide data on ARTAG for research purposes. 
 
















Neuropathologic assessment of neurodegenerative conditions and the aging brain is 
witnessing a renaissance. Novel bodily fluids and neuroimaging biomarkers are being 
developed, which require constant diagnostic certainty established by neuropathological 
assessment [32]. In parallel, in the last two decades, molecular pathology has entered the 
diagnostic practice with the application of new disease markers. New disease concepts and 
diagnostic criteria have emerged. The National Institute on Aging (NIA) in collaboration with 
the Alzheimer’s Association (AA) revised consensus guidelines for the neuropathologic 
assessment of Alzheimer disease (AD) [28]. The concept of primary age-related tauopathy 
(PART) was published, which focuses on the evaluation and interpretation of neurofibrillary 
tangle (NFT) pathology in the medial temporal lobe [12]. Although pathological accumulation 
of abnormally phosphorylated tau protein in astrocytes has been frequently noted in the aging 
brain [22, 24, 30], a consensus on how to describe these was not available for the 
neuropathology community. In addition, clinicians and biomarker researchers were not aware 
of this type of tau pathology. To stimulate clinicopathological studies and research into the 
pathobiology of astrocytic tau pathology, an international group of neuropathologists and 
researchers published a strategy for the harmonized consensus evaluation of aging-related tau 
astrogliopathy (ARTAG)[21]. This strategy includes four steps: i) identification of subpial, 
subependymal, perivascular, white and gray matter types of ARTAG; ii) documentation of the 
regional involvement such as medial temporal lobe, lobar, subcortical, or brainstem; iii) 
description of subregional involvement; and iv) documentation of the severity [21].  
 
Interlaboratory studies of the BrainNet Europe Consortium to evaluate the reproducibility of 
the assessments of various neuropathological variables have shown that there are many 
factors leading to inconsistencies, such as different fixation or staining methods [5], but also 
differences in the interpretation of immunoreactive morphologies or staging systems [2-4, 6, 
7]. Therefore, evaluation of the reproducibility of consensus guidelines is still required. 
Indeed, AD neuropathologic evaluation yielded data that have high agreement with potential 
modifications for modest improvements [27].  
 
The spectrum of astroglial tau pathologies expands beyond ARTAG and comprise various 
morphologies thought to be characteristic for so called primary frontotemporal lobar 
degeneration (FTLD)-tauopathies [19, 20]. Accordingly, tufted astrocytes are associated with 
progressive supranuclear palsy (PSP) [13, 17], astrocytic plaques with corticobasal 
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degeneration (CBD)[13, 15], globular astroglial inclusions with globular glial tauopathies 
(GGT)[1], and ramified astrocytes with Pick’s disease (PiD)[14]. Most of these have been 
defined using silver staining and later by immunohistochemical studies using different 
antibodies against different modifications of the tau protein [16]. In ARTAG, two 
morphologies of astroglial tau immunoreactivities have been dfined: the thorn-shaped 
astrocytes (TSAs) and the granular/fuzzy astrocytes (GFAs)[21]. The bushy astrocytes 
reported in argyrophilic grain disease (AGD)[9] were included in the morphological spectrum 
of GFAs. In addition to ARTAG, there is a lack of studies on how consistently can 
neuropathologists recognize astrocytic tau immunoreactivities of primary tauopathies. Based 
on these, we set up a study to evaluate how consistently neuropathologists recognize i) 
different astroglial tau immunoreactivities including those of ARTAG and those associated 
with primary tauopathies; ii) ARTAG types; and iii) the severity of ARTAG.  
 
Material and methods 
Case selection and evaluation 
For this study twenty-two cases were selected from the Brain Bank of the Institute of 
Neurology, Medical University of Vienna. Cases with PSP, CBD, PiD, GGT and combined 
age-related pathologies (e.g. ARTAG, PART, AD, AGD) were included. The latter cases 
were selected from the ongoing longitudinal VITA (Vienna Transdanubian Ageing) study 
[22]. Neuropathological data of the cases included in the study are summarized in Table 1. 
The same cases were used for studies 1 and 2 A and B (see below). 
 
For study 1 in sum thirty-five microphotographs (x400; 15x 11.3 cm 300 dpi) of astrocytic tau 
(AT8) immunoreactivities were provided from seventeen cases (Table 1). The evaluators had 
to choose from six different tau-morphologies (i.e. tufted astrocyte, astrocytic plaque, 
globular astroglial inclusion, ramified astrocyte, GFA, and TSA) or as a seventh option “none 
of these“. The first and, if felt equivocal, the second most likely morphology had to be 
selected.   
 
In addition a set of AT8-immunostained sections were scanned (study 2 A, B) and made 
available for download (courtesy of Histotech3D, Hungary) for each neuopathologist 
participating in the study. The images and sections were evaluated alone or in small (2-3) 
groups of neuropathologists in different Departments and Institutions. In sum twenty-five 
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AT8-immunostained sections were scanned from twenty cases (Table 1). The Digital Slide 
Viewer Application was suitable for Windows and MacOs systems. The sections represented 
different ARTAG types showing different severity but also sections from primary tauopathy 
cases have been included. For each case a separate excel sheet was provided (see online 
supplemental file 1). For gray and white matter, ARTAG specific anatomical regions were 
asked. The evaluators had i) to decide whether ARTAG is present (yes/no); ii) to indicate 
which type of ARTAG is present (yes/no question for each type); iii) to indicate for each 
ARTAG type visible on the section whether the severity/extent is occasional or numerous; iv) 
to indicate for each ARTAG type visible on the section if numerous is focally accentuated or 
widespread; and v) to indicate whether other non-ARTAG type of astroglial tau 
immunoreactivity is seen in the section or not (yes/no).  
 
Neuropathologists at different sites were blinded to the overall neuropathological diagnosis 
for each case. Examples of the different forms of ARTAG and astrocytic tau 
immunoreactivities and also a table summarizing the key features of each type of pathology 
were provided as published recently [21]. A reference group (GGK, JQT, EBL, DJI, JLR, V , 
JBT, DS) evaluated all images and scanned sections to reach a consensus. This meeting was 
held in the Department of Pathology and Laboratory Medicine, Center for Neurodegenerative 
Disease Research, Institute on Aging, University of Pennsylvania School of Medicine, 
Philadelphia, PA, USA.  
 
Statistical analysis  
Percentage (%) of agreement with 95% confidence interval (CI) was calculated for each 
evaluation and also for the mean % of agreements. In addition, a weighted kappa value [11] 
was calculated to assess agreement between each rater’s response and the reference opinion, 
resulting in 45 kappa values for each study. Then the overall Kappa value was generated by 
averaging the 45 kappa values and the 95% confidence interval was generated using the 
bootstrap procedure. The bootstrap resampling method was performed by resampling cases 
1000 times. The above process was done for ten different study questions (Table 2). When a 
kappa value can’t be generated for a particular rater due to no variation of his/her responses 
for all sub-questions in a given study, Maxwell's random error coefficient of agreement [25] 
was applied as an alternative. Kappa value or Maxw ell’s statistic above 0.75 was considered 
“excellent” agreement, 0.4–0.75 as “good” agreement, and below 0.4 as “poor” agreement. 
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Both kappa value and Maxwell‘s statistic correct for random chance agreement, and thus they 




Evaluation of astrocytic tau immunoreactivities 
For 35 images (Fig. 1) the reference group defined the astrocytic morphology (Table 3): 11 
GFA, 10 TSA, 4 of each astrocytic plaques and tufted astrocytes and 3 of each globular 
astroglial inclusions and ramified astrocytes. For six images (i.e., 6, 10, 15, 16, 19, and 20) 
the reference group provided a second option (Table 3) since the image was not equivocal. 
For 24 images the agreement was above 60%, including 9 out of 10 (9/10) images of TSAs, 
7/11 of GFAs, 4/4 of astrocytic plaques, 2/4 of tufted astrocytes, 2/3 of globular astroglial 
inclusions and 1/3 images of ramified astrocytes. Less agreement was reached for 1 out of 10 
TSA, 4/11 GFAs, 2/4 tufted astrocytes, 1/3 globular astrocytic inlcusions and for 2/3 ramified 
astrocytes.  
 
Astrocytic plaques were interpreted only by a few evaluators as GFA, globular astroglial 
inclusion, or as unclassifiable astrocytic morphology. One image (Nr. 12) of a globular 
astroglial inclusion was interpreted as astrocytic plaque by 37.78% of the evaluators. This 
image was taken from the amygdala of an elderly individual showing no further 
neuropathological features of either GGT or CBD. The reference group felt that the distinct 
globular structures in the astrocytic processes had to be distinguished from a GFA 
morphology, which has fine granular deposits. Since the tau immunoreactivity was seen in the 
proximal segments of the astrocyte, the possibility of this image representing an astrocytic 
plaque was not raised by the reference group. GFAs were mostly interpreted as astrocytic 
plaques or rarely as TSAs or tufted astroctyes, while TSAs were interpreted with the widest 
range of possible astrocytic morphologies (Table 3). Ramified astrocytes photographed from 
Pick´s disease cases were interpreted as TSA or tufted astrocyte by some of the evaluators. 
Finally tufted astrocytes photographed from cases showing the neuropathological features of 
PSP, were interpreted as ramified astrocytes, GFA or TSA by a few evaluators. In summary 
the overall % agreement for study I was above 60% with a kappa value of 0.54 (95% CI 





Recognition of ARTAG and other astrogliopathies 
Evaluation of 25 scanned tau-immunostained sections revealed high agreement whether 
ARTAG pathology is present or not (Table 4). In this series three cases with 
neuropathological features of either PSP or CBD were included. Indeed, in these three cases 
was the least agreement. Scan Nr. 9 represented the basal ganglia from a case showing 
ARTAG and PSP. While the presence of ARTAG was recognized by 68.29% of the 
evaluators, only 26.83% recognized tufted astrocytes in the section. Precise evaluation of the 
section revealed astrocytes compatible with GFAs (Fig. 2a) and also tufted astrocytes (Fig. 
2b). Scan 16 represented temporal cortex from a case with CBD (Figs. 2c, d): here more than 
50% of evaluators thought ARTAG was also present. Regarding scan 19, the section of the 
temporal cortex was evaluated from a case with PSP; while ARTAG was recognized, only 
52.5% agreed that tufted astrocytes could be seen as well. Finally, for scan 21, approximately 
30% of the evaluators felt that the scan showed astrocytic plaques; the reference opinion was 
that only occasional GFAs were noted in the scanned temporal cortex. In spite the high % of 
agreement regarding the recognition of ARTAG and other astrogliopathies, kappa values were 
lower for these (0.48, 95% CI 0.457, 0.900; and 0.24, 95% CI 2.89E-16, 0.374; 
respectively)(Table 2). 
  
Recognition of ARTAG types 
Next we examined the agreement of the recognition of different ARTAG types. For each 
subpial, subependymal, gray and white matter, and perivascular ARTAG high agreement was 
reached (approximately 80%), with kappa values ranging from 0.37-0.71 (Table 2). Only a 
few examples can be listed where considerable disagreement was observed (Table 5). 
Regarding ARTAG in scans 3, 10, and 25 the reference group thought that the tau 
immunoreactive dots in subpial (Fig. 3a), subependymal (Fig. 3c), or perivascular (Fig. 3e) 
locations, respectively, were not sufficient to call ARTAG. On the other hand, in scan 13 
occasional subpial TSAs (Fig. 3b), in scan 24 subependymal (Fig. 3d) and in scan 7 
perivascular (Fig. 3f) TSAs and thick astrocytic processes were recognized and interpreted as 
ARTAG. In scan 17 the reference group did not interpret the tau immunoreactivity in the 
white matter as ARTAG, but rather as oligodendroglial coiled bodies (Fig. 4a, b). On the 
other hand, in scan 20, the reference group interpreted the tau immunoreactivity in the white 
matter in the vicinity of the inferior ventricle as white matter ARTAG (Fig. 4c, d).  Regarding 
scan 10, the reference group did not interpret the single astrocytic-like tau immunoreactivity 
(Fig. 4e) in the dentate gyrus as ARTAG, while in the CA4 region similar immunoreactivities 
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were interpreted as such, leading to disagreement (Table 5). On the other hand, in scan 13, 
TSAs in the dentate gyrus were interpreted as ARTAG (Fig. 4f) with a high level of 
agreement (80.49%). In scan 12 several neuritic plaque-related tau profiles were observed in 
the inferior temporal gyrus (Fig. 4g), and due to the unequivocal characteristics of GFAs or 
TSA, were not interpreted as ARTAG. In the temporal cortex as seen in scan 15, occasional 
GFAs (Fig. 4h) were interpreted as ARTAG with high agreement (72.5 %; Table 5). Finally, 
in scan 12, ARTAG was seen in both the hippocampal dentate gyrus (Fig. 4i) and the CA4 
subregion (Fig. 4j), however with different agreement among raters (87.8% versus 70.73%).  
 
Evaluation of the severity and extent of ARTAG 
In all scans where ARTAG was observed, severity was scored in a total of 90 locations by the 
reference group. Agreement for these 90 locations ranged from 12.5 to 87.5% (mean 50.49%) 
with a kappa value of 0.39±0.049 (Table 2). Next we evaluated the agreement to decide 
whether the severity is occasional or numerous, without further stratification of numerous for 
focally accentuated or widespread. For this the agreement was better (ranged from 22.5-
100%) with a mean agreement of 65.9% (Table 2).  
 
Finally, the overall assessment of ARTAG pathologies (all aforementioned aspects 
calculated) revealed 82.3% percentage of agreement and a kappa value of 0.59 (95% CI 
0.534, 0.653) (Table 2). 
 
Discussion 
The goal of this study was to evaluate the variation in the neuropathologic assessment of 
ARTAG. While several studies have been conducted to determine interrater variability of 
AD-related neuropathological changes or Lewy body pathologies [3, 27], there was a paucity 
of data how astrocytic tau immunoreactivities are described. In spite the definition of tufted 
astrocytes and astrocytic plaques as hallmark lesions of PSP and CBD [13], respectively, the 
spectrum of astrocytic tau immunoreactive morphologies expand beyond these two, even 
within PSP and CBD. Some of these morphologies are thought to represent early forms of 
tufted astrocytes [29], analogous to the concept of pretangles preceding neurofibrillary tangles 
[8]. Further astrocytic morphologies have been described in primary FTLD-tauopathies, such 
as the ramified astrocytes in PiD [14] and globular astrocytic inclusions in GGT [1]. The 
recent consensus statement on the evaluation of ARTAG aimed to harmonize the description 
of astrocytic tau morphologies and added GFAs and TSAs to this spectrum of tau 
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immunoreactivities [21]. Importantly, our study revealed that the overall assessment of 
ARTAG shows a good agreement (kappa: 0.59, 95% CI 0.534, 0.653) between raters across 
multiple international centres.  
 
To be able to include researchers and neuropathologists from all over the world we decided to 
use the cost-effective method of digital pathology, which is already widely applied for some 
diagnostic aspects, including post mortem neuropathology evaluations. Our first study 
focused on images of single astrocytic tau immunoreactivities, and the second on the 
evaluation of scanned slides. We are aware that evaluating single images and scans of 
circumscribed anatomical regions might have led to a certain proportion of disagreement. In 
the recent study on the multisite assessment of NIA-AA criteria of AD-related pathologies, 
whole-slide images decreased the performance for the evaluation of severity and scores of 
amyloid- plaques [27]. On the other hand with this approach in the current study we wer
able to eliminate bias during the evaluation of cases. This means, for example, that if the 
evaluator looks across many anatomical regions and decides that the diagnosis is PSP or 
CBD, then the spectrum of astrocytic morphologies may be overlooked or not described in 
detail, with most classified as tufted astrocytes or astrocytic plaques, respectively. Our study, 
however, was able to show that GFA type morphologies in the gray matter occur in both PSP 
and CBD, suggesting that these have a pathogenic relation to the tau lesions in primary 
FTLD-tauopathies. Importantly, several cases included in this study were above 85 years of 
age where some evaluators suspected primary FTLD tauopathy-related astrocytic tau 
pathologies. Therefore, evaluating only a small number of anatomical regions or brain 
biopsies for the diagnosis of neurodegenerative diseases could potentially lead to 
misinterpretations in the classification of astrocytic pathologies. We noted variability in the 
evaluation of ramified astrocytes, which were either under-recognized, or in some cases, 
TSAs and tufted astrocytes were misinterpreted for these ramified morphologies. This might 
be due to the fact that PiD is a rare disorder, which shows variability in the presence and 
severity of astrocytic tau immunoreactivity [14, 18, 23]. Indeed, ramified astrocytes are less 
studied astrocytic morphologies. Although we cannot exclude that ramified astrocytes are 
present in the ageing brain without the classical neuronal tau pathology characteristic of PiD, 
these astrocytes frequently show 3R tau isoform immunoreactivity in PiD [16, 23], which 
might be useful tool to reconcile these discrepancies. Some degree of difficulty was also 
observed for the recognition of individual TSAs in microphotographs. This was not a problem 
for scanned sections when, depending on the location (i.e., subpial, subependymal, 
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perivascular), even without the classical thorny appearance, astrocytes were interpreted as 
ARTAG. Accordingly, when single astrocytic tau morphologies are evaluated in these 
locations, the TSA-like appearance may be more ambiguous and might not be recognized in 
all cases. 
 
The least agreement was observed for the evaluation of severity and extent of ARTAG. While 
the distinction between occasional and numerous was better, there are several aspects, which 
need to be addressed. For the original recommendation for the description of ARTAG 
severity, instead of the widely used three-tiered semiquantitative strategy (mild, moderate, 
severe) we aimed to concede that ARTAG astrocytes may be focally accentuated (e.g. subpial 
TSAs in cortical areas in the depths of sulci) or may appear throughout (i.e., widespread) the 
gray matter as GFAs, or in the white matter as TSAs. Many evaluators expressed difficulty in 
describing the situation when single gray matter GFAs or subpial TSAs are seen following the 
cortical ribbon with 500-2000 m distance between them: whether this is to be interpreted as 
widespread even if the amount of astrocytes on a birds-eye view is not numerous. The way 
one has to manipulate the digital slides, such as zooming in and out, may have also 
contributed to the discordance in determining the amount of ARTAG. It is a challenge to 
incorporate the different distribution patterns of ARTAG in a simple scoring system, 
especially that morphometry methods are difficult to develop that distinguish between 
neuronal and astrocytic tau immunoreactivities.  
 
Considering all aspects we recommend the following strategy with modest changes as 
compared to the original ARTAG consensus harmonization paper [21]:  
1) After the recognition of the morphology of astrocytic tau immunoreactivity using high 
magnification (x200-x400), the extent of involvement in a selected anatomical area should be 
evaluated using low magnification (x50-x100);  
2) If the occasional tau immunoreactive astrocytes appear in a circumscribed area of the 
specific anatomical region then it should designated as “occasional” (score 1, corresponding 
to mild in a semiquantitative evaluation strategy);  
3) If the occasional tau immunoreactive astrocytes are scattered throughout the anatomical 
region then it should be designated as “widespread” with the note that the degree is 
mild/moderate (score 2, corresponding to moderate in a semiquantitative evaluation strategy); 
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4) If numerous tau immunoreactive astrocytes appear in a circumscribed area of the specific 
anatomical region then it should designated as “numerous, focally accentuated” (score 2, 
corresponding also to moderate in a semiquantitative evaluation strategy); 
5) If numerous tau immunoreactive astrocytes appear throughout the anatomical region then it 
should be designated as “numerous widespread” (score 3, corresponding to severe in a 
semiquantitative evaluation strategy). 
 
For several evaluations we observed considerable discrepancy between the % of agreement 
and the calculated kappa values. This is because kappa value corrects for random chance 
agreement, while percentage of agreement does not. Thus kappa value is a more conservative 
summary measure than percentage agreement. 
 
In summary, we find that application of a harmonized consensus evaluation strategy for the 
description of ARTAG [21] yields a good inter-rater agreement and good comparison across 
research and neuropathology sites. Improvement is needed regarding comparable evaluations 
of the severity and extent of ARTAG types. Our study suggests that the spectrum of co-
existing astrocytic tau immunoreactivities might be wider than generally assumed in primary 
FTLD-tauopathies if more care is taken to describe the morphologies. This concept does not 
weaken the diagnostic importance of tufted astrocytes, astrocytic plaques, ramified astrocytes 
and globular astrocytic inclusions as specific morphologies associated with certain primary 
FTLD-tauopathies. On the other hand this notion might help to better understand the 
pathogenic relevance of ARTAG and its relation to primary FTLD-tauopathies or other 
disease conditions with astrocytic tau pathologies such as chronic traumatic encephalopathy 
[26]. Overall, our study supports the application of the current harmonized consensus 
evaluation strategy of ARTAG [21] with a slight modification of the evaluation of its severity 
and extent. This allows collection and comparison of worldwide data on ARTAG for research 
purposes. 
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Legend to Tables 
Table 1. Clinicopathological data of the cases included in study 1 (evaluation of photos) and 
study 2 A and B (evaluation of scanned sections). Abbreviations: m: male; f: female; 
CERAD: Consortium to Establish a Registry for Alzheimer Disease; Cx: cortex. Braak stage 
refers to neurofibrillary degeneration [10] and Thal phase to A deposition [31]. *indicates 
that presence of subcortical neurofibrillary tangles were suggestive of early form of PSP; 
**indicates that ARTAG was represented by single GFAs.   
 
Table 2. Summary of kappa values (± 95 confidence interval, CI) and mean % of agreement 
(± 95 CI) for different aspects of study I and II. 
 
Table 3. Reference opinion and interrater agreement (% of agreement ± 95 confidence 
interval, CI) for the microphotographs (1-35) representing astroglial tau immunoreactivities. 
GAI:globular astrocytic inclusion; AP: astrocytic plaque; TA: tufted astrocyte; RA: ramified 
astrocyte. 
 
Table 4. Interrater agreement (% of agreement ± 95 confidence interval, CI) for the 
recognition of ARTAG and other astroglial tau pathologies. Note that for case 14, only 14 
evaluations were received due to technical reasons. 
 
Table 5. Interrater agreements (AGR; % of agreement ± 95 confidence interval, CI) for 
different ARTAG types (SP: subpial; SE: subependymal; PV: perivascular; WM: white 
matter; GM: gray matter) in different anatomical regions (TEM: temporal; FRO: frontal; IC: 
internal capsule; FRB: frontobasal; MES: mesencephalon; MED-MID: medulla oblongata 
midline; PYR: pyramid; AMY: amygdala; CING: anterior cingulate; CAUD: caudate; ACC: 
accumbens; HYPOG: hypoglossal nucleus; CA1-4: cornu ammonus 1-4 subregion; GYAMB: 










Legend to figures 
Figure 1. Microphotographs used in study 1. The numbering corresponds to that listed in 
Table 2 with the reference opinion. Arrows indicate the astroglial tau immunoreactivities that 
were specifically asked to be evaluated. 
Figure 2. Representative images of tau immunoreactive astrocytes in cases where the 
interrater agreement was less than in others when the presence of ARTAG had to be decided. 
GFA (A) and TA (B) in the striatum in case 9. Astrocytic plaques (C, D) in a case 16 
(corticobasal degeneration). Astrocytic tau immunoreactivities (E) in a case 19 with early 
form of PSP with an example of a tufted astrocyte (left upper) and granular/fuzzy astrocyte 
(right lower) in image F. Occasional GFAs in the temporal cortex in case 21 (G, H). 
Figure 3. Representative images of different ARTAG types where discrepancy was observed 
between the reference opinion and the evaluations (see also Table 4). In scans 3, 10 and 25 
the reference group did not interpret the fine dots (arrows) as subpial (A), subependymal (C), 
or perivascular (E) ARTAG, respectively. On the other hand, in cases 13, 24 and 7 thorny 
astrocytes and thick astrocytic processes (arrows) were interpreted as subpial (B), 
subependymal (D) and perivascular (F) ARTAG, respectively.  
Figure 4. Representative images of different ARTAG types where discrepancy was observed 
between the reference opinion and the evaluations (see also Table 4). In scan 17 the reference 
group did not interpret the tau immunoreactivity in the white matter as ARTAG but rather as 
oligodendroglial coiled bodies (A; enlarged in B). In scan 20 the reference group interpreted 
the tau immunoreactivity in the white matter in the vicinity of the inferior ventricle as white 
matter ARTAG (C, D).  In scan 10 the reference group did not interpret the single astrocytic-
like tau immunoreactivity (E; arrow) as ARTAG leading to disagreement. In scan 13 thorny 
astrocytes in the dentate gyrus were interpreted as ARTAG (F). Neuritic plaque tau profiles in 
the temporal cortex (G) were not interpreted as ARTAG in case 12. In the temporal cortex of 
case 15, occasional granular/fuzzy astrocytes (H) were interpreted as ARTAG. In scan 12 
ARTAG was seen in both the hippocampal dentate gyrus (I) and the CA4 subregion (J) but 
with different levels of agreement.  
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Case-1 80 f + 3 1 1 + + - - - - 
  
1 
     
1 
     







   
4 5 6 
Case-3 87 f + 3 1 1 - + - - - - 
    
11,12 
      
7 
  
 Case-4 89 f + 3 2 1 + + - - - - 
    
13,14 
      
8 
  
 Case-5 83 f + 6 5 3 + + +* - - - 
     
15,16 
      
9 
 
 Case-6 83 f + 3 2 2 + + - - - - 
  
17-19 
       
10 
   
 Case-7 85 m + 2 1 1 + + - - - - 
    
20 
      
11 
  
 Case-8 77 m + 3 2 2 + + - - - - 
   
21 
    
12 
    
25 
 Case-9 82 m + 5 3 2 + + + - - - 
   
22 
      
13 
   
 Case-10 86 m + 5 3 3 + + - - - - 
   
23 
      
14 
   
 Case-11 82 m + 3 1 1 + + - - - - 
 
24 
     
17 
      
 Case-12 79 m + 4 3 2 - - - + - - 
  
25, 28, 30 
     
16 
     
 Case-13 76 f + 2 0 0 - - + - - - 
  
26,27,29 
     
19 
     
 Case-14 88 f + 4 3 3 + + - - - - 
 
31 
     
22 
      
 Case-15 63 f - - - - - - - - + - 
 
32,34 
            
 Case-16 55 m - - - - - - - - - + 
  
33 
           
 Case-17 65 f - - - - - - - - - + 
  
35 
           
 Case-18 82 f + 2 1 1 - + - - - - 
          
15 
   
 Case-19 87 f + 3 0 0 + + +* - - - 





 Case-20 85 m + 1 0 0 - + - - - - 
          
20 
   
 Case-21 81 m + 1 0 0 - +** - - - - 
        
21 
     




Study and question 
Kappa 
value 95% CI 
Mean % of 
agreement 95% CI 
1: Recognition of astrocytes 0.54 0.433, 0.645 63.8 ±7.5 
2A: Recognition of presence of ARTAG 0.48 0.457, 0.900 91.1 ±5.1 
2A: Recognition of other astrogliopathy 0.24 2.89E-16, 0.374 73.1 ±6.3 
2A: Recognition of SP ARTAG 0.60 0.468, 0.739 81.8 ±7.02 
2A: Recognition of SE ARTAG 0.71 0.584, 0.828 87.2 ±5.9 
2A: Recognition of GM ARTAG 0.37 0.288, 0.536 83.1 ±5.6 
2A: Recognition of WM ARTAG 0.44 0.323, 0.551 79.5 ±6.05 
2A: Recognition of PV ARTAG 0.57 0.442, 0.672 78.1 ±6.4 
2B: Semiquantitative scoring 0.39 0.341, 0.445 50.4 (65.9) ±3.8 (4.6) 
































































































































1 GFA 97.78 ±4.31 - - - TA 2.22 
2 GFA 73.33 ±12.9 - - - TA 11.1 
3 GFA 62.22 ±14.1 - - - TSA 26.67 
4 TSA 84.44 ±10.5 - - - GFA 4.44 
5 TSA 91.11 ±8.32 - - - TA, RA, GFA 2.22 
6 GFA 68.89 ±13.5 TSA 86.67 ±11.2 TSA 17.78 
7 GFA 64.44 ±13.9 - - - RA 22.22 
8 GFA 37.78 ±14.1 - - - TSA 37.78 
9 TSA 75.56 ±12.5 - - - RA, GFA 6.67 
10 TSA 64.44 ±13.9 GFA 64.44 ±13.9 RA 28.89 
11 TSA 77.78 ±12.1 - - - GAI 11.11 
12 GAI 42.22 ±14.4 - - - AP 37.78 
13 TSA 80.00 ±11.6 - - - TA, GFA 11.11 
14 GFA 60.00 ±14.3 - - - AP 26.67 
15 RA 44.44 ±14.5 TA 57.78 ±14.4 TSA 24.44 
16 TA 24.44 ±12.5 RA 35.56 ±13.9 GFA, TSA 24.44 
17 AP 73.33 ±12.9 - - - GFA 13.33 
18 GFA 68.89 ±13.5 - - - AP 15.56 
19 GFA 6.67 ±7.28 RA 28.89 ±13.2 TSA 31.11 
20 GFA 31.82 ±13.6 AP 86.36 ±10.0 AP 54.55 
21 TSA 68.89 ±13.5 - - - GFA 15.56 
22 TSA 73.33 ±12.9 - - - RA, GAI, GFA 6.67 
23 TSA 57.78 ±14.4 - - - GAI 24.44 
24 TSA 71.11 ±13.2 - - - GFA 15.56 
25 AP 88.89 ±9.19 - - - GAI 6.67 
26 TA 44.44 ±14.5 - - - RA 26.67 
27 TA 62.22 ±13.9 - - - RA 24.44 
28 AP 80.00 ±11.1 - - - Uncl 6.67 
29 TA 68.89 ±13.5 - - - RA, Uncl 8.89 
30 AP 88.89 ±9.19 - - - Uncl 4.44 
31 GFA 40.00 ±14.3 - - - AP 40.00 
32 GAI 91.11 ±8.32 - - - GFA 6.67 
33 RA 8.89 ±8.31 - - - TSA 68.89 
34 GAI 91.11 ±8.32 - - - Uncl, TSA, GFA, TA 2.22 





Table 4.  
Scan ARTAG Agreement 95%CI Other AG Agreement 95%CI Nr of evaluations 
1 yes 95.12 ±6.59 no 78.05 ±12.67 41 
2 yes 100.00 0 no 75.00 ±13.42 40 
3 yes 100.00 0 no 80.00 ±12.4 40 
4 yes 100.00 0 no 87.50 ±10.25 40 
5 yes 100.00 0 no 82.50 ±11.78 40 
6 yes 100.00 0 no 85.00 ±11.07 40 
7 yes 80.00 ±12.4 no 62.50 ±15 40 
8 yes 100.00 0 no 75.00 ±13.42 40 
9 yes 68.29 ±14.24 TA 26.83 ±13.56 41 
10 yes 92.68 ±7.97 no 63.41 ±14.74 41 
11 yes 100.00 0 no 80.49 ±12.13 41 
12 yes 92.68 ±7.97 no 87.80 ±10.02 41 
13 yes 95.12 ±8.45 no 80.49 ±12.13 41 
14 yes 100.00 0 no 100.00 0 14 
15 yes 100.00 0 no 77.50 ±12.94 40 
16 no 48.78 ±15.3 AP 63.41 ±14.74 41 
17 yes 77.50 ±12.94 no 60.00 ±15.18 40 
18 yes 92.50 ±8.16 no 77.50 ±12.94 40 
19 yes 80.00 ±12.4 TA 52.50 ±15.48 40 
20 yes 100.00 0 no 95.00 ±6.75 40 
21 yes 70.00 ±14.2 no 67.50 ±14.51 40 
22 yes 92.50 ±8.16 no 47.50 ±15.48 40 
23 yes 100.00 0 no 67.50 ±14.51 40 
24 yes 97.50 ±4.84 no 65.00 ±14.78 40 



























Region GM AGR 
95%
CI 
1 no 92.68 ±7.97 no 100.00 ±0 no 95.12 ±6.59 1 TEM no 53.66 ±15.2 1 TEM yes 92.68 ±7.97 
2 yes 95.00 ±6.75 no 100.00 0 yes 80.00 ±12.4 2 TEM yes 97.50 ±4.84 2 TEM yes 97.50 ±4.84 
3 no 27.50 ±13.8 no 75.00 ±13.4 yes 60.00 ±15.1 3 FRO yes 92.50 ±8.1 3 FRO yes 100.00 0 
4 yes 90.00 ±9.3 yes 70.00 ±14.2 yes 92.50 ±8.16 4 IC yes 77.50 ±12.9 4 CAUD yes 100.00 0 
5 yes 97.50 ±4.84 yes 100.00 0 yes 97.50 ±4.84 4 FRB yes 100.00 0 4 ACC yes 100.00 0 
6 yes 100.00 0 yes 95.00 ±6.75 yes 97.50 ±4.84 5 MES yes 92.50 ±8.1 4 FRB yes 100.00 0 
7 yes 72.50 ±13.8 no 72.50 ±13.8 yes 37.50 ±15.0 6 MED-MID yes 97.50 ±4.8 5 MES yes 97.50 ±4.84 
8 yes 95.00 ±6.75 yes 100.00 0 yes 92.50 ±8.16 6 PYR yes 100.00 0 6 HYPOG yes 100.00 0 
9 no 95.12 ±6.59 no 97.56 ±4.72 no 78.05 ±12.6 7 AMY yes 72.50 ±13.8 7 AMY yes 75.00 ±13.4 
10 yes 73.17 ±13.5 no 51.22 ±15.3 no 75.61 ±13.1 8 AMY yes 95.00 ±6.75 8 AMY yes 100.00 0 
11 yes 92.68 7±.97 no 78.05 ±12.7 yes 58.54 ±15.0 9 IC no 73.17 ±13.5 9 CAUD yes 65.85 ±14.5 
12 yes 82.93 ±11.2 yes 65.85 ±14.5 yes 56.10 ±15.1 10 TEM no 78.05 ±12.6 10 CA1-4 yes 58.54 ±15.0 
13 yes 70.73 ±13.9 yes 90.24 ±9.08 yes 56.10 ±15.1 11 AMY yes 68.29 ±14.2 10 DG no 51.22 ±15.3 
14 no 85.71 ±10.8 no 100.00 0 yes 64.29 ±14.8 12 TEM yes 92.68 ±7.97 10 TEM yes 82.93 ±11.5 
15 yes 100.00 0 no 57.50 ±15.3 yes 82.50 ±11.7 13 TEM yes 92.68 ±7.97 11 AMY yes 85.37 ±10.8 
16 no 58.54 ±15.0 no 95.12 6.59 no 85.37 ±10.8 14 TEM yes 100.00 0 11 GYAMB yes 80.49 ±12.1 
17 no 90.00 ±9.3 no 100.00 0 no 90.00 ±9.3 15 TEM yes 97.50 ±4.84 12 CA1-4 yes 70.73 ±13.9 
18 no 60.00 ±15.1 no 92.50 ±8.16 no 75.00 ±13.4 16 TEM no 63.41 ±14.7 12 DG yes 87.80 ±10.0 
19 no 70.00 ±14.2 no 100.00 0 no 95.00 ±6.75 17 FRO no 42.50 ±15.3 12 TEM no 34.15 ±14.5 
20 yes 100.00 0 yes 95.00 ±6.75 yes 65.00 ±14.7 18 CING yes 87.50 ±10.2 13 CA1-4 no 43.90 ±15.1 
21 no 77.50 ±12.9 no 100.00 0 no 97.50 ±4.84 19 TEM yes 65.00 ±14.7 13 DG yes 80.49 ±12.1 
22 no 92.50 ±8.16 no 100.00 0 no 97.50 ±4.84 20 TEM no 55.00 ±15.4 13 TEM yes 78.05 ±12.6 
23 no 56.41 ±15.5 no 84.62 ±11.3 no 76.92 ±13.2 20 HIPP yes 87.50 ±10.2 14 CA1-4 no 85.71 ±10.8 
24 yes 97.50 ±4.84 yes 70.00 ±14.2 yes 75.00 ±13.4 21 TEM no 82.50 ±11.7 14 DG no 92.86 ±7.98 
25 yes 72.50 ±13.8 no 90.00 ±9.3 no 72.50 ±13.8 22 FRO yes 62.50 ±15.0 14 TEM no 64.29 ±14.8 
          
23 IC no 58.97 ±15.4 15 CA1-4 yes 87.50 ±10.2 
          
23 FRB yes 92.31 ±8.36 15 DG yes 92.50 ±8.16 
          
24 IC no 72.50 ±13.8 15 TEM yes 72.50 ±13.8 
          
24 FRB yes 92.50 ±8.16 16 TEM no 63.41 ±14.7 
          
25 MES no 42.50 ±15.3 17 FRO yes 77.50 ±12.9 
               
18 CING yes 90.00 ±9.3 
               
19 TEM yes 80.00 ±12.4 
               
20 CA1-4 yes 85.00 ±11.0 
               
20 DG yes 100.00 0 
               
20 TEM yes 92.50 ±8.16 
               
21 TEM yes 67.50 ±14.5 
               
22 FRO yes 92.50 ±8.16 
               
23 CAUD yes 94.87 ±6.92 
23 
 
               
23 ACC yes 89.74 ±9.52 
               
23 FRB yes 87.18 ±10.4 
               
24 CAUD yes 92.50 ±8.16 
               
24 ACC yes 85.00 ±11.0 
               
24 FRB yes 90.00 ±9.3 
                              25 MES yes 95.00 ±6.75 
 
 
 
 
